Thermo Fisher Scientific on Thursday morning reported a 19 percent increase in first quarter revenues, driven by growth in most of its business segments.
MDxHealth reported after the close of the market Wednesday a 21 percent increase in first quarter 2022 sales.
Qiagen on Tuesday afternoon reported strong first quarter revenues that blew by Wall Street estimates, driven by growth in its molecular diagnostics business.
Exact Sciences reported after the close of the market on Tuesday that its first quarter revenues rose 21 percent year over year.
On April 27, Autobio, BSBE, Easy Diagnosis, Medicalsystem, Dian Diagnostics, Hybribio and Kingmed released 2022 Q1 report.
Wondfo, BGI, Leadman, Sinocare, ACROBiosystems, NanoMicro released 2022 Q1 Report
On April 24, Shanghai Universal Biotech's released its 2021 annual report. The report shows that in 2021, the company will achieve operating income of CNY 1.110 billion, a year-on-year increase of 30.69%.
Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022.
April 25, Swiss drugmaker Roche's (ROG.S) first quarter sales rose a better-than-expected 10% on strong U.S. demand for rapid COVID-19 antigen tests and drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia.
For the three months ending March 31, total revenue was 74,283.49 million CNY compared to 39.53% growth in the year-ago period with the total profit of 35, 813.66 million CNY compared to 76.23% growth over the same period last year.
✔ All (240)
✔ Press release (0)
✔ Industry news (240)
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.